AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...

Less than a month after reports of takeover talks between AbbVie and Gilgamesh Pharma first emerged, the pair have gone public with details of a $1.2 billion deal – but it is not an acquisition. It ...

AbbVie will pay up to US$1.2 billion to acquire Gilgamesh’s short-acting psychedelic bretisilocin, highlighting growing industry interest in hallucinogenic drugs for the treatment of psychiatric ...

AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones.

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. AbbVie on Monday said it ...

AbbVie acquires bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion, enhancing its psychiatric care portfolio. Gilgamesh will spin out a new entity to retain its remaining programs ...

One of Australia's newest operas, Gilgamesh, has been crowned the biggest winner of the 2025 Art Music Awards in a ceremony held in Sydney on 21 August. Other winners include former ABC Classic ...